What has Karonga taught us? Tuberculosis studied over three decades.
- 1 February 2009
- journal article
- Vol. 13 (2), 153-64
Abstract
This paper summarises tuberculosis (TB) research over almost 30 years in Karonga District, northern Malawi, an area typical of much of rural Africa. The dominant factor has been the human immunodeficiency virus (HIV), which arrived in the district about 1980, leading to an increase in TB incidence to a peak of approximately 65 smear-positive pulmonary cases per 100000 population in 2000. Tuberculin surveys indicate annual risks of Mycobacterium tuberculosis infection of approximately 1%; thus, most of the population is uninfected and at risk of primary infection and disease. Molecular epidemiological studies demonstrate that about two thirds of TB arises from recent infection, but recognisable recent contact is responsible for only about 10% of disease. By 2001, 57% of TB was directly attributable to HIV, implying that it would have declined were it not for HIV. HIV infection increases the risk of TB most among young adults, and greatly increases the risk of recurrence from new infection after treatment. Mortality rates in the HIV-infected are high, but there is no association of HIV with drug resistance. Other risk factors with relatively smaller effects include age and sex, contact, several genetic polymorphisms and area. Neither one nor two doses of the bacille Calmette-Guérin (BCG) vaccine provides protection against adult pulmonary TB, despite protecting against leprosy. Skin test surveys, cohort studies and comparative immunological studies with the UK suggest that exposure to environmental mycobacteria provides some protection against TB and that BCG's failure is attributable partly to this widespread heterologous exposure masking effects of the vaccine. Drug resistance has remained constant (<10%) over more than 20 years. Immunotherapy with M. vaccae provided no benefits, but treatment of HIV-positive patients with cotrimoxazole reduced mortality. The Karonga programme illustrates the value of long-term population-based studies to investigate the natural history of TB and to influence TB control policy. Current studies focus on immunological markers of infection, disease and protection, and on elucidating the impact of antiretroviral treatment on TB incidence at population level.This publication has 81 references indexed in Scilit:
- Determinants of Cluster Size in Large, Population-Based Molecular Epidemiology Study of Tuberculosis, Northern MalawiEmerging Infectious Diseases, 2008
- Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in MalawiThe Lancet, 2008
- CD209 Genetic Polymorphism and Tuberculosis DiseasePLOS ONE, 2008
- HIV epidemic trend and antiretroviral treatment need in Karonga District, MalawiEpidemiology and Infection, 2007
- The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette–Guérin vaccination in southern England and northern MalawiClinical and Experimental Immunology, 2006
- Tuberculosis Transmission Attributable to Close Contacts and HIV Status, MalawiEmerging Infectious Diseases, 2006
- Distribution of Environmental Mycobacteria in Karonga District, Northern MalawiApplied and Environmental Microbiology, 2006
- Mycobacterial Purified Protein Derivatives Stimulate Innate Immunity: Malawians Show Enhanced Tumor Necrosis Factor Alpha, Interleukin-1β (IL-1β), and IL-10 Responses Compared to Those of Adolescents in the United KingdomInfection and Immunity, 2004
- Estimating the relative recurrence risk ratio using a global cross‐ratio modelGenetic Epidemiology, 2003
- Molecular Epidemiology and Drug Resistance of Mycobacterium tuberculosis Isolates from Ethiopian Pulmonary Tuberculosis Patients with and without Human Immunodeficiency Virus InfectionJournal of Clinical Microbiology, 2002